Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and SteinCares, a specialty healthcare company in Latin America, have signed a new agreement to commercialize a proposed biosimilar of dupilumab across Latin America.

Under the agreement, Bio-Thera will be responsible for product development and supply, while SteinCares will lead the registration and commercialization process throughout Latin America.

Dupilumab is one of the top five medicines globally in terms of annual sales value, so this biosimilar is a significant milestone in SteinCares’ expansion. The new partnership will potentially support the treatment of chronic inflammatory conditions in both adults and children.

“Expanding access to advanced therapies while making healthcare more affordable is central to our mission,” said Mitchell Waserstein, CEO at SteinCares. “Through this collaboration, we are reinforcing our position as one of the region’s most robust biosimilar platforms in Latin America, offering a broad portfolio and pipeline tailored to the needs of patients and health systems across the region.”

“This collaboration underscores our continued trust in SteinCares as a regional partner with strong regulatory, commercial, and medical capabilities,” added Dr. Shengfeng Li, CEO of Bio-Thera Solutions. “By leveraging well-established commercial network of SteinCares, we aim to accelerate the delivery of safe, high-quality and affordable therapies to patients across Latin America.”